Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.

Early Breast Cancer Trialists’ Collaborative group (EBCTCG) None., (2021), Lancet Oncol, 22, 1139 - 1150

Breast tumour volume and blood flow measured by MRI after one cycle of epirubicin and cyclophosphamide-based neoadjuvant chemotherapy as predictors of pathological response.

Stevens W. et al, (2021), Br J Radiol

Locoregional Therapy for the Primary Tumour in Women with a De Novo Diagnosis of Metastatic Breast Cancer

Miller K. et al, (2021), Current Breast Cancer Reports

Treatment variation in early breast cancer in the UK.

Dodwell D. et al, (2020), BMJ, 371

Surgery of the primary tumour in women with metastatic breast cancer at diagnosis in England and Wales – how do treatment rates vary at an individual and regional level?

Miller K. et al, (2020), European Journal of Cancer, 138, S116 - S117

Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study.

Mannu GS. et al, (2020), BMJ, 369

Initiation of adjuvant chemotherapy and trastuzumab for human epidermal growth receptor 2-positive early invasive breast cancer in a population-based cohort study of older women in England

DODWELL D., (2020), Journal of Geriatric Oncology

Addressing frailty in patients with breast cancer: A review of the literature

Jauhari Y. et al, (2020), European Journal of Surgical Oncology, 46, 24 - 32

Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastuzumab (LANTERN): a Phase II Randomised Trial

Seligmann JF. et al, (2020), Clinical Oncology

Immediate and delayed autologous abdominal microvascular flap breast reconstruction in patients receiving adjuvant, neoadjuvant or no radiotherapy: a meta‐analysis of clinical and quality‐of‐life outcomes

Khajuria A. et al, (2019), BJS Open

Eligibility for Partial Breast Radiotherapy in England.

Taylor CW. et al, (2019), Clin Oncol (R Coll Radiol)

Endocrine therapy in the years following a diagnosis of breast cancer: A proof of concept study using the primary care prescription database linked to cancer registration data.

Emanuel G. et al, (2019), Cancer Epidemiol, 61, 185 - 189

International Variation in Criteria for Internal Mammary Chain Radiotherapy.

Duane FK. et al, (2019), Clin Oncol (R Coll Radiol)

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) None., (2019), Lancet, 393, 1440 - 1452

Adjuvant treatment for breast cancer

Flatley MJ. and Dodwell DJ., (2019), Surgery (United Kingdom)

The SMALL Trial: A Big Change for Small Breast Cancers

Morgan J. et al, (2019), Clinical Oncology

Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project.

Thompson AM. et al, (2018), Eur J Cancer, 101, 210 - 219

Should patients with ductal carcinoma in situ be treated with adjuvant whole breast radiotherapy after breast conservation surgery?

Bagenal J. et al, (2018), BMJ, 361

Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ.

Maxwell AJ. et al, (2018), Eur J Surg Oncol, 44, 429 - 435

Neoadjuvant chemotherapy for early breast cancer - Author's reply.

McGale P. et al, (2018), Lancet Oncol, 19

Load More

Include forthcoming?